---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-007217"
form_type: "8-K"
ticker: "BYSI"
cik: "0001677940"
company_name: "BeyondSpring Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:17:51.345001+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BeyondSpring Q3 2025 net loss $1.7M; Plinabulin DCR 85% in NSCLC post-PD-1/L1

## Summary
- Net loss from continuing ops $1.7M vs $2.2M YoY; cash $12.5M up from $2.9M Dec 2024.
- Plinabulin + docetaxel + Keytruda in NSCLC: DCR 85%, median PFS 7.0 mo, 12-mo OS 79%.
- SEED (38% owned) closed $30M Series A-3, FDA/NMPA IND clearance for RBM39 degrader.
- R&D $1.0M, G&A $0.8M; headcount reductions drove lower admin expenses.
- Discontinued ops (SEED sale accounting) net loss $3.2M in Q3 2025.

## SEC filing metadata
- accession: 0001171843-25-007217
- form_type: 8-K
- ticker: BYSI
- cik: 0001677940
- company_name: BeyondSpring Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677940/000117184325007217/0001171843-25-007217-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677940/000117184325007217/f8k_111225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-007217
- JSON: https://secwatch.observer/filing/0001171843-25-007217.json
- Plain text: https://secwatch.observer/filing/0001171843-25-007217.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.